FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Gupta Pramod
 2. Date of Event Requiring Statement (Month/Day/Year)
07/12/2021		 3. Issuer Name and Ticker or Trading Symbol
Unicycive Therapeutics, Inc. [UNCY]
(Last)
(First)
(Middle)
C/O UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL SUITE A-32		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
EVP, Pharma and Business Ops
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

LOS ALTOS, CA 94022		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy)   (1) 10/01/2029 Common Stock 52,326 $ 3.27 D  
Employee Stock Option (right to buy)   (2) 12/30/2029 Common Stock 23,256 $ 3.27 D  
Employee Stock Option (right to buy)   (3) 04/06/2030 Common Stock 58,140 $ 3.27 D  
Employee Stock Option (right to buy)   (4) 03/01/2031 Common Stock 23,256 $ 7.01 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Gupta Pramod
C/O UNICYCIVE THERAPEUTICS, INC.
5150 EL CAMINO REAL SUITE A-32
LOS ALTOS, CA 94022		       EVP, Pharma and Business Ops  

Signatures

/s/ Pramod Gupta 07/12/2021
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Twenty-five percent (25%) of the stock options vested on October 1, 2020, and the remaining seventy-five percent (75%) of the stock options have vested and will continue to vest in successive equal monthly installments over the following thirty-six (36) months, until the options become fully vested on October 1, 2023.
(2) Twenty-five percent (25%) of the stock options vested on January 1, 2021, and the remaining seventy-five percent (75%) of the stock options have vested and will continue to vest in successive equal monthly installments over the following thirty-six (36) months, until the options become fully vested on January 1, 2024.
(3) Twenty-five percent (25%) of the stock options vested on April 6, 2021, and the remaining seventy-five percent (75%) of the stock options have vested and will continue to vest in successive equal monthly installments over the following thirty-six (36) months, until the options become fully vested on April 6, 2024.
(4) Twenty-five percent (25%) of the stock options vest on March 1, 2022, and the remaining seventy-five percent (75%) of the stock options vest in successive equal monthly installments over the following thirty-six (36) months, until the options become fully vested on March 1, 2025.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.